Curis Announces Presentations Related to CUDC-907 and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Curis Announces Presentations Related to CUDC-907 and Erivedge® at 2016 ASCO Annual Meeting

LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq: CRIS ), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that a Phase 2 trials-in-progress poster for CUDC-907, Curis' proprietary drug candidate in development for treatment of patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) with MYC gene alterations, will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from June 3-7 in Chicago, IL.

In addition, data will be presented from clinical studies of Erivedge ® , a first-in-class drug approved for the treatment of patients with advanced basal cell carcinoma (BCC). Roche and Genentech, a member of the Roche Group, develop and commercialize Erivedge under a collaboration agreement with Curis.

Additional information on the presentations can be found below and abstracts can be accessed at  www.asco.org .

CUDC-907 Poster Presentation:
             
Date/Time:           Monday, June 6, 8 AM – 11:30 AM CDT
Abstract Number:           TPS7579
Presentation Title:           Phase 2, open-label study of CUDC-907 with and without rituximab in patients with relapsed/refractory MYC-altered diffuse large B cell lymphoma
Erivedge ® Poster Presentations:
             
Date/Time:           Poster Session: Saturday, June 4, 1 PM – 4:30 PM CDT
            Poster Discussion Session: Saturday, June 4, 4:45 PM – 6 PM CDT
Abstract Number:           9509
Presentation Title:           Mikie: A randomized, double-blinded, regimen-controlled, phase 2 study to assess the efficacy and safety of two different vismodegib (VISMO) regimens in patients (pts) with multiple basal cell carcinomas (BCCs)
             
Date/Time:           Saturday, June 4, 1 PM – 4:30 PM CDT
Abstract Number:           9532
Presentation Title:           Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts)       
             

About Curis, Inc. Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology.  As part of this collaboration, Curis has exercised options to exclusively license oral small molecule antagonists of PD-L1/ VISTA and IRAK4. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com .

For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6597 jdentzer@curis.com Media Contact David Schull Russo Partners (212) 845-4271 david.schull@russopartnersllc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 107

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 138

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 53

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 70

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Microinsurance Market Expected to Surpass $11 Billion by 2034

Updated Category News Views 137

Growth Trajectory of the Global Microinsurance Market The microinsurance market is witnessing remarkable transformation as consumer demands shift towards financial inclusion, coupled with increasing awareness of the myriad advantages insurance provides. This positive trend is fueled by government initiatives aimed at regulation and expansion of microinsurance offerings,...

Continue Reading
Ormat Technologies Launches Secondary Stock Offering

Updated Category News Views 188

Ormat Technologies Launches Secondary Stock Offering Ormat Technologies, Inc. (NYSE: ORA), renowned for its innovative geothermal and renewable energy solutions, recently announced an exciting development in the investment realm—the initiation of an underwritten secondary offering. This offering encompasses a total of 3,700,000 shares of common stock on behalf of ORIX...

Continue Reading
MongoDB Executive Share Transactions Highlight Growth Potential

Updated Category News Views 132

Insights from MongoDB Executive Share Transactions Cochran Hope F, a director at MongoDB, Inc. (NASDAQ: MDB), recently made notable moves with the company's Class A Common Stock, and these transactions were disclosed in the latest SEC filings. This activity has attracted attention from investors. In September, the director sold 1,174 shares at $224.38 each, which brought...

Continue Reading
Essential Guidance for Navigating Hurricane Travel Risks

Updated Category News Views 69

Essential Guidance for Navigating Hurricane Travel Risks Hurricane season brings with it the potential for severe weather that can disrupt travel plans and lead to significant financial losses. As storms like Hurricane Helene have shown, the impact can be widespread, devastating homes and infrastructure, particularly in the southeastern regions. During these turbulent...

Continue Reading
Ascend Performance Materials Launches High-Purity Production

Updated Category News Views 279

Ascend Performance Materials Starts High-Purity Acrylonitrile Production Ascend Performance Materials has recently announced an exciting new phase in its production capabilities. The company is now producing high-purity acrylonitrile at its Chocolate Bayou facility. This advancement comes after the successful installation and commissioning of state-of-the-art purification...

Continue Reading